This inventor holds 2 USPTO granted patents, plus 1 CIPO patent and 2 EPO patents. Top assignees: Bioprojet, Sun Pharma Advanced Research Company Limited. Active years: 2014-2016.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Location History:
- Baroda, IN (2014)
- Vadodara, IN (2016)
Company Filing History:
2 out of 24 
2 out of 66 
Years Active: 2014-2016
Title: **Muthukumaran Natarajan Pillai: Pioneering Research in S1P Receptor Agonists**
Introduction
Muthukumaran Natarajan Pillai is an esteemed inventor based in Vadodara, India, recognized for his significant contributions to the field of medicinal chemistry. With a focus on innovative compounds that act on S1P (sphingosine-1-phosphate) receptors, he holds two notable patents that serve to address various medical needs.
Latest Patents
Among his latest patents, Pillai has developed novel compounds known as "Piperidinyl monocarboxylic acids as S1P1 receptor agonists." This invention details innovative compounds that act as agonists at S1P receptors, alongside compositions containing these compounds and their medicinal applications. His other significant patent is titled "Dicarboxylic acid derivatives as S1P1 receptor agonists." This technology encompasses new compounds that possess agonistic activity at S1P receptors, as well as their synthesis processes and use as immunosuppressive agents. Additionally, this invention aims to provide pharmaceutical compositions for the treatment and prevention of immune-mediated and inflammatory diseases.
Career Highlights
Muthukumaran Pillai has built a robust career, with meaningful contributions to pharmaceutical research. He has worked with significant players in the industry, including Bioprojet and Sun Pharma Advanced Research Company Limited. His work in these companies has considerably advanced the understanding and development of S1P receptor modulators.
Collaborations
Throughout his career, Pillai has collaborated with esteemed colleagues, including Marc Capet and Isabelle Berrebi-Bertrand. These collaborations have facilitated the exchange of knowledge and expertise, fostering an environment conducive to innovation and breakthroughs in medical research.
Conclusion
Muthukumaran Natarajan Pillai exemplifies dedication to innovation in the realm of pharmacology. His pioneering patents and industry collaborations showcase his commitment to advancing medical science, particularly through the development of S1P receptor agonists. As the landscape of medical treatments continues to evolve, Pillai's contributions highlight the vital role of inventors in shaping the future of healthcare.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile